pyrroles has been researched along with Abdominal Migraine in 61 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.64) | 18.2507 |
| 2000's | 3 (4.92) | 29.6817 |
| 2010's | 8 (13.11) | 24.3611 |
| 2020's | 49 (80.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ailani, J; Dabruzzo, B; Finnegan, M; Guo, H; Lipton, RB; Lu, K; Miceli, R; Schwedt, TJ; Severt, L; Silberstein, SD; Tassorelli, C; Trugman, JM | 1 |
| Boinpally, R; Lu, K | 2 |
| Deeks, ED | 1 |
| Blumenfeld, AM; Butler, M; Dodick, DW; Knievel, K; Lai, H; Manack Adams, A; Severt, L | 1 |
| Dai, Q; Meng, J; Tao, X; Wang, W; Wang, Z; Yan, Z; Zhou, Q | 1 |
| Balasundaram, MK; Singh, A | 1 |
| Avallone, R; Ferrari, A; Rustichelli, C | 1 |
| Adams, A; Brin, MF; Burstein, R; Houle, TT; Melo-Carrillo, A; Strassman, AM | 1 |
| da Silva, MRR; Dos Santos, JBR | 1 |
| Dodick, DW; Lateiner, JE; Lipton, RB; Revicki, DA; Shewale, AR; Singh, RBH; Zhao, S | 1 |
| Harris, PWR; Hay, DL; Walker, CS | 1 |
| Altamura, C; Brunelli, N; Fofi, L; Marcosano, M; Vernieri, F | 1 |
| Blumenfeld, AM; Dabruzzo, B; Dodick, DW; Finnegan, M; Li, Y; Lipton, RB; Lu, K; McAllister, P; Miceli, R; Pozo-Rosich, P; Severt, L; Trugman, JM | 1 |
| Belger, M; Johansson, E; Polavieja, P; Venkata, SK; Wilhelm, S | 1 |
| Ailani, J; Bedrin, K | 1 |
| Coric, V; Croop, R; Harris, L; Johnston, KM; L'Italien, G; Popoff, E; Powell, L | 1 |
| Abreu, J; Li, D; Tepper, SJ | 1 |
| Ashina, M; Dabruzzo, B; Gandhi, P; Halker Singh, RB; Lipton, RB; Ma, J; McVige, J; Mechtler, L; Stokes, J; Yu, SY | 1 |
| Schoenfuss, ES | 1 |
| Ailani, J; Dodick, DW; Finnegan, M; Lipton, RB; Lu, K; Szegedi, A; Trugman, JM | 2 |
| Bosch, R; DeAngelis, M; Jones, CJ; Kleijn, HJ; Kothare, PA; Kowalski, K; Li, CC; Michelson, D; Voss, T; Xie, I; Xu, Y; Yang, B | 1 |
| Ankrom, W; Bondiskey, P; Dockendorf, MF; Jakate, A; Kraft, WK; Li, CC; Liu, W; Marcantonio, EE; Matthews, C; Mesens, S; Palcza, J; Panebianco, D; Reynders, T; Wagner, JA | 1 |
| Ailani, J; Butler, M; Finnegan, M; Hutchinson, S; Knievel, K; Lipton, RB; Lu, K; Severt, L; Trugman, JM; Yu, SY | 1 |
| Capi, M; Cipolla, F; Cisale, GY; Curto, M; Lionetto, L; Martelletti, P | 1 |
| Scott, LJ | 1 |
| Ailani, J; Dodick, DW; Halker Singh, RB; Lipton, RB; Shewale, AR; Trugman, JM; Viswanathan, HN; Yu, SY; Zhao, S | 1 |
| Chen, M; Chen, Z; Gao, B; Sun, Y; Wang, Z; Yang, Y | 1 |
| Goadsby, PJ; Moreno-Ajona, D; Pérez-Rodríguez, A | 1 |
| Tepper, D | 1 |
| Boinpally, R; Butler, M; Jakate, A; Lu, K; McGeeney, D; Periclou, A | 1 |
| Dhir, A | 1 |
| Druyts, E; Franklin, M | 1 |
| Agboola, F; Atlas, SJ; Borrelli, EP; Pearson, SD; Rind, DM; Touchette, DR | 1 |
| Boinpally, R; Bondiskey, P; Colón-González, F; Dockendorf, MF; Kraft, WK; Liu, W; Matthews, CZ; Min, KC; Mixson, L; Panebianco, D; Xu, J | 1 |
| Adams, AM; Brin, MF; Burstein, R; Melo-Carrillo, A; Schain, AJ; Strassman, AM | 1 |
| Blumenfeld, AM; Dodick, DW; Goadsby, PJ; Jakate, A; Kalidas, K; Lipton, RB; Liu, C; M Adams, A; Szegedi, A; Trugman, JM | 1 |
| Baek, IH; Ha, DK; Han, N; Kim, MJ; Kwak, JH | 1 |
| Chen, L; Diao, Y; Du, B; Du, Y; Liu, Y; Shu, Y; Zhang, Z | 1 |
| Blumenfeld, AM; Dodick, DW; Finnegan, M; Goadsby, PJ; Hutchinson, S; Liu, C; Szegedi, A; Trugman, JM | 1 |
| Blumenfeld, AM; Boinpally, R; Borbridge, L; Butler, M; Contreras-De Lama, J; Jakate, A; Lipton, RB; McGeeney, D; Periclou, A | 1 |
| Blumenfeld, AM; Hutchinson, S; Lipton, RB; Lu, K; Severt, L; Silberstein, SD; Yu, SY | 1 |
| Falk, N; Garland, S; Nedd, M; Wilk, A | 1 |
| Coric, V; Croop, R; Dabirvaziri, P; Deighton, A; Harris, L; Johnston, K; L'Italien, G; Moren, J; Popoff, E; Thiry, A | 1 |
| Leung, L; Liao, S; Wu, C | 1 |
| Ailani, J; Finnegan, M; Goadsby, PJ; Guo, H; Lipton, RB; Miceli, R; Severt, L; Trugman, JM | 1 |
| Diener, HC; Jørgensen, K; Tfelt-Hansen, P | 1 |
| Bateman, KP; Bosch, R; Dockendorf, M; Jones, C; Kleijn, HJ; Kothare, PA; Kowalski, K; Li, CC; Marcantonio, EE; Thornton, B; Voss, T; Xie, I; Xu, Y; Yang, B | 1 |
| Tepper, SJ | 1 |
| Loder, E; Tfelt-Hansen, P | 1 |
| Giamberardino, MA; Martelletti, P | 1 |
| Ashina, M; Do, TP; Guo, S | 1 |
| Assaid, C; Aurora, SK; Bachman, R; Dodick, DW; Dupre, N; Ge, JY; Lipton, RB; Michelson, D; Voss, T | 1 |
| Fang, Y; Li, X; Lin, J; Ren, L; Wang, X; Yin, Z; Zhang, A | 1 |
| Branchek, TA; Cohen, ML; Erickson, JA; Filla, SA; Johnson, KW; Mathes, BM; Nelson, DL; Phebus, LA; Schaus, JM; Schenck, KW; Wainscott, DB; Zgombick, JM | 1 |
| López Serrano, R; Otero Uribe, JL | 1 |
| Cumberbatch, MJ; Hargreaves, RJ; Hill, RG | 1 |
21 review(s) available for pyrroles and Abdominal Migraine
| Article | Year |
|---|---|
Atogepant: First Approval.
Topics: Calcitonin Gene-Related Peptide Receptor Antagonists; Drug Approval; Drug Interactions; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Spiro Compounds; United States; United States Food and Drug Administration | 2022 |
Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials.
Topics: Calcitonin Gene-Related Peptide Receptor Antagonists; Clinical Trials, Phase III as Topic; Humans; Migraine Disorders; Pyridines; Pyrroles; Treatment Outcome | 2022 |
The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials.
Topics: Analgesics; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Spiro Compounds; Treatment Outcome | 2022 |
Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety.
Topics: Analgesics; Calcitonin Gene-Related Peptide; Double-Blind Method; Headache; Humans; Migraine Disorders; Multicenter Studies as Topic; Piperidines; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Spiro Compounds; Treatment Outcome | 2022 |
Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review.
Topics: Adult; Analgesics; Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Quality of Life; Spiro Compounds | 2022 |
Gepants - a long way to cure: a narrative review.
Topics: Antibodies, Monoclonal; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Spiro Compounds | 2022 |
Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings.
Topics: Adult; Benzamides; Double-Blind Method; Female; Humans; Middle Aged; Migraine Disorders; Network Meta-Analysis; Piperidines; Pyridines; Pyrroles; Randomized Controlled Trials as Topic | 2022 |
Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm.
Topics: Adult; Bayes Theorem; Benzamides; Dizziness; Double-Blind Method; Humans; Migraine Disorders; Nausea; Piperidines; Pyridines; Pyrroles; Serotonin Receptor Agonists; Treatment Outcome | 2022 |
A Brief Review of Gepants.
Topics: Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Pyridines; Pyrroles; Raynaud Disease | 2023 |
Ubrogepant for the treatment of migraine.
Topics: Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Clinical Trials, Phase III as Topic; Humans; Migraine Disorders; Pyridines; Pyrroles; Treatment Outcome | 2020 |
Ubrogepant: First Approval.
Topics: Administration, Oral; Calcitonin Gene-Related Peptide Receptor Antagonists; Drug Approval; Humans; Migraine Disorders; Pyridines; Pyrroles | 2020 |
Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials.
Topics: Adult; Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Pyridines; Pyrroles; Randomized Controlled Trials as Topic | 2020 |
Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?
Topics: Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Comparative Efficacy of Oral Calcitonin-Gene-Related Peptide Antagonists for the Treatment of Acute Migraine: Updated Meta-analysis.
Topics: Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Pyridines; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis.
Topics: Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Time Factors | 2021 |
Ubrogepant: An Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for Abortive Migraine Treatment.
Topics: Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Pyridines; Pyrroles | 2022 |
Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis.
Topics: Adult; Benzamides; Humans; Migraine Disorders; Network Meta-Analysis; Piperidines; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Topics: Antibodies, Monoclonal, Humanized; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Clinical Trials as Topic; Drug Delivery Systems; Humans; Migraine Disorders; Pyridines; Pyrroles; Receptors, Calcitonin Gene-Related Peptide; Translational Research, Biomedical; Treatment Outcome | 2018 |
The Emperor's New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful?
Topics: Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles | 2019 |
Advances in orally administered pharmacotherapy for the treatment of migraine.
Topics: Administration, Oral; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Tryptamines | 2019 |
Therapeutic novelties in migraine: new drugs, new hope?
Topics: Analgesics; Animals; Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Tryptamines | 2019 |
20 trial(s) available for pyrroles and Abdominal Migraine
| Article | Year |
|---|---|
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
Topics: Analgesics; Double-Blind Method; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Spiro Compounds; Treatment Outcome | 2022 |
Evaluation of the Pharmacokinetic Interaction and Safety of Ubrogepant Coadministered With Esomeprazole Magnesium.
Topics: Adult; Esomeprazole; Female; Humans; Male; Migraine Disorders; Pyridines; Pyrroles | 2022 |
Single-Dose Pharmacokinetics and Safety of Ubrogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial.
Topics: Adult; Humans; Liver Diseases; Migraine Disorders; Pyridines; Pyrroles | 2022 |
Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Analgesics; Double-Blind Method; Female; Humans; Male; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Spiro Compounds; Treatment Outcome | 2022 |
Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial.
Topics: Calcitonin Gene-Related Peptide Receptor Antagonists; Drug Administration Schedule; Humans; Migraine Disorders; Patient Reported Outcome Measures; Piperidines; Pyridines; Pyrroles; Quality of Life; Spiro Compounds | 2023 |
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.
Topics: Adult; Aged; Analgesics; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Nausea; Pain; Pain Management; Pyridines; Pyrroles; Young Adult | 2019 |
Making Better Dose Decisions: Using Exposure-Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment.
Topics: Adolescent; Adult; Aged; Clinical Decision-Making; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Models, Biological; Pain Measurement; Pyridines; Pyrroles; Time Factors; Treatment Outcome; Young Adult | 2020 |
Ubrogepant for the Treatment of Migraine.
Topics: Adult; Calcitonin Gene-Related Peptide Receptor Antagonists; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyperacusis; Kaplan-Meier Estimate; Male; Migraine Disorders; Nausea; Pain Management; Photophobia; Pyridines; Pyrroles | 2019 |
Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males.
Topics: Adolescent; Adult; Alanine Transaminase; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Healthy Volunteers; Humans; Liver Function Tests; Male; Middle Aged; Migraine Disorders; Pyridines; Pyrroles; Reference Values; Young Adult | 2020 |
Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Calcitonin Gene-Related Peptide Receptor Antagonists; Chemical and Drug Induced Liver Injury; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Migraine Disorders; Pyridines; Pyrroles | 2020 |
Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II.
Topics: Acute Disease; Adult; Calcitonin Gene-Related Peptide Receptor Antagonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Patient Reported Outcome Measures; Patient Satisfaction; Pyridines; Pyrroles | 2020 |
Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans.
Topics: Adult; Calcitonin Gene-Related Peptide Receptor Antagonists; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Migraine Disorders; Pyridines; Pyrroles; Sumatriptan; Tryptamines | 2020 |
Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults.
Topics: Administration, Oral; Adult; Alanine Transaminase; Dose-Response Relationship, Drug; Double-Blind Method; Female; Healthy Volunteers; Humans; Liver; Liver Function Tests; Male; Middle Aged; Migraine Disorders; Piperidines; Placebos; Pyridines; Pyrroles; Spiro Compounds; Young Adult | 2021 |
Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Pain; Pyridines; Pyrroles; Treatment Outcome | 2021 |
Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.
Topics: Adult; Calcitonin Gene-Related Peptide Receptor Antagonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Outcome Assessment, Health Care; Pyridines; Pyrroles; Serotonin 5-HT1 Receptor Agonists | 2021 |
Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Calcitonin Gene-Related Peptide; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Migraine Disorders; Pyridines; Pyrroles | 2021 |
Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II.
Topics: Adult; Calcitonin Gene-Related Peptide Receptor Antagonists; Cardiovascular Diseases; Double-Blind Method; Female; Heart Disease Risk Factors; Humans; Male; Migraine Disorders; Pain; Pyridines; Pyrroles; Risk Factors; Treatment Outcome | 2021 |
Atogepant for the Preventive Treatment of Migraine.
Topics: Adolescent; Adult; Aged; Calcitonin Gene-Related Peptide Receptor Antagonists; Constipation; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Migraine Disorders; Nausea; Piperidines; Pyridines; Pyrroles; Spiro Compounds; Young Adult | 2021 |
Population PK Analyses of Ubrogepant (MK-1602), a CGRP Receptor Antagonist: Enriching In-Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling.
Topics: Adult; Calcitonin Gene-Related Peptide Receptor Antagonists; Dose-Response Relationship, Drug; Dried Blood Spot Testing; Female; Humans; Middle Aged; Migraine Disorders; Pyridines; Pyrroles; Surveys and Questionnaires | 2018 |
A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.
Topics: Adult; Calcitonin Gene-Related Peptide Receptor Antagonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Pyridines; Pyrroles; Treatment Outcome | 2016 |
20 other study(ies) available for pyrroles and Abdominal Migraine
| Article | Year |
|---|---|
Atogepant.
Topics: Analgesics; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Spiro Compounds | 2022 |
Atogepant (Qulipta) for migraine prevention.
Topics: Administration, Oral; Calcitonin Gene-Related Peptide Receptor Antagonists; Drug Interactions; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Receptors, Calcitonin Gene-Related Peptide; Signal Transduction; Spiro Compounds; Treatment Outcome | 2021 |
Atogepant: an emerging treatment for migraine.
Topics: Adult; Antibodies, Monoclonal; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Spiro Compounds | 2022 |
Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSD.
Topics: Animals; Bayes Theorem; Calcitonin Gene-Related Peptide; Male; Migraine Disorders; Nerve Fibers, Unmyelinated; Nociceptors; Piperidines; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Spiro Compounds | 2022 |
Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials.
Topics: Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Personal Satisfaction; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Serotonin 5-HT1 Receptor Agonists; Tryptamines | 2022 |
Atogepant (Qulipta®) for migraine prevention.
Topics: Analgesics; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Spiro Compounds | 2022 |
Atogepant for migraine.
Topics: Analgesics; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Spiro Compounds | 2022 |
Treating acute migraine with ubrogepant.
Topics: Humans; Migraine Disorders; Pyridines; Pyrroles | 2023 |
Gepants.
Topics: Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Spiro Compounds | 2020 |
Lasmiditan (Reyvow) and ubrogepant (Ubrelvy) for acute treatment of migraine.
Topics: Animals; Benzamides; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles | 2020 |
Ubrogepant to treat migraine.
Topics: Adult; Calcitonin Gene-Related Peptide Receptor Antagonists; Humans; Migraine Disorders; Pyridines; Pyrroles | 2020 |
ICER's assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine.
Topics: Benzamides; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles | 2020 |
The effectiveness and value of novel acute treatments for migraine.
Topics: Analgesics; Benzamides; Calcitonin Gene-Related Peptide; Cost-Benefit Analysis; Drug Costs; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Quality-Adjusted Life Years; Receptor, Serotonin, 5-HT1F; Receptors, Serotonin; Serotonin 5-HT1 Receptor Agonists; Signal Transduction; Systematic Reviews as Topic; Time Factors; Treatment Outcome | 2020 |
Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons.
Topics: Analgesics; Animals; Botulinum Toxins, Type A; Calcitonin; Humans; Migraine Disorders; Nerve Fibers, Unmyelinated; Piperidines; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Spiro Compounds | 2021 |
To Probe the Binding Interactions between Two FDA Approved Migraine Drugs (Ubrogepant and Rimegepant) and Calcitonin-Gene Related Peptide Receptor (CGRPR) Using Molecular Dynamics Simulations.
Topics: Calcitonin Gene-Related Peptide; Humans; Migraine Disorders; Molecular Docking Simulation; Molecular Dynamics Simulation; Pharmaceutical Preparations; Piperidines; Pyridines; Pyrroles; Receptors, Calcitonin Gene-Related Peptide | 2021 |
Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacks.
Topics: Benzamides; Controlled Clinical Trials as Topic; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles | 2022 |
Atorvastatin attenuates NF-kappaB activation in trigeminal nucleus caudalis in a rat model of migraine.
Topics: Analysis of Variance; Animals; Atorvastatin; Blotting, Western; Cell Nucleus; Disease Models, Animal; Dose-Response Relationship, Drug; Fluorescent Antibody Technique; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Migraine Disorders; Neoplasm Proteins; Neurons; NF-kappa B; Nitroglycerin; Nucleocytoplasmic Transport Proteins; Pyrroles; Rats; Rats, Sprague-Dawley; Trigeminal Caudal Nucleus | 2009 |
Novel potent 5-HT(1F) receptor agonists: structure-activity studies of a series of substituted N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amides.
Topics: Administration, Oral; Animals; Blood Proteins; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; In Vitro Techniques; Migraine Disorders; Piperidines; Polyunsaturated Alkamides; Pyridines; Pyrroles; Rabbits; Radioligand Assay; Receptor, Serotonin, 5-HT1F; Receptors, Serotonin; Saphenous Vein; Serotonin Receptor Agonists; Structure-Activity Relationship; Trigeminal Nerve; Vasoconstriction | 2003 |
[Do statins have benefit on migraine].
Topics: Adult; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Migraine Disorders; Pyrroles | 2006 |
The effects of 5-HT1A, 5-HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Analgesics; Animals; Electric Stimulation; Male; Migraine Disorders; Oxazoles; Oxazolidinones; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin Receptor Agonists; Trigeminal Caudal Nucleus; Tryptamines | 1998 |